Cargando…

Immunomodulatory Effects Associated with Cladribine Treatment

Cladribine is a synthetic deoxyadenosine analogue with demonstrated efficacy in patients with relapsing-remitting multiple sclerosis (MS). The main mechanism of action described for cladribine is the induction of a cytotoxic effect on lymphocytes, leading to a long-term depletion of peripheral T and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fissolo, Nicolás, Calvo-Barreiro, Laura, Eixarch, Herena, Boschert, Ursula, Espejo, Carmen, Montalban, Xavier, Comabella, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700070/ https://www.ncbi.nlm.nih.gov/pubmed/34943995 http://dx.doi.org/10.3390/cells10123488

Ejemplares similares

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Therapeutic Effect of IL-21 Blockage by Gene Therapy in Experimental Autoimmune Encephalomyelitis
por: Edo, Ángel, et al.
Publicado: (2022)

A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis
por: Calvo-Barreiro, Laura, et al.
Publicado: (2020)

Treatment with MOG-DNA vaccines induces CD4(+)CD25(+)FoxP3(+) regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis
por: Fissolo, Nicolás, et al.
Publicado: (2012)

Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis
por: Calvo-Barreiro, Laura, et al.
Publicado: (2021)

Regulatory Lymphocytes Are Key Factors in MHC-Independent Resistance to EAE
por: Marín, Nieves, et al.
Publicado: (2014)

Hsp70 Regulates Immune Response in Experimental Autoimmune Encephalomyelitis
por: Mansilla, M. José, et al.
Publicado: (2014)

Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis
por: Fissolo, Nicolás, et al.
Publicado: (2022)

Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis
por: Malhotra, Sunny, et al.
Publicado: (2015)

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
por: Stuve, Olaf, et al.
Publicado: (2019)

Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor
por: Miralles, Marta, et al.
Publicado: (2017)

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment
por: Kalatskaya, Irina, et al.
Publicado: (2023)

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy
por: Wiendl, Heinz, et al.
Publicado: (2022)

Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status
por: Carlini, Federico, et al.
Publicado: (2021)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

Chitinase 3-like 1 is neurotoxic in primary cultured neurons
por: Matute-Blanch, Clara, et al.
Publicado: (2020)

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study
por: Montalban, Xavier, et al.
Publicado: (2018)

Neurofilament light chain level is a weak risk factor for the development of MS
por: Arrambide, Georgina, et al.
Publicado: (2016)

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
por: Schmierer, Klaus, et al.
Publicado: (2022)

Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple Sclerosis
por: Malhotra, Sunny, et al.
Publicado: (2011)

Chitinases and chitinase-like proteins as biomarkers in neurologic disorders
por: Pinteac, Rucsanda, et al.
Publicado: (2020)

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells
por: Gil-Varea, Elia, et al.
Publicado: (2020)

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients
por: Malhotra, Sunny, et al.
Publicado: (2018)

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Liquid Biopsy in Neurological Diseases
por: Malhotra, Sunny, et al.
Publicado: (2023)

Application of population pharmacokinetics to cladribine
por: Lindemalm, Synnöve, et al.
Publicado: (2005)

Cladribine: Lymphopenia: case report
Publicado: (2021)

CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS
por: Fissolo, Nicolás, et al.
Publicado: (2021)

CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
por: Comabella, Manuel, et al.
Publicado: (2021)

Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS
por: de Stefano, Nicola, et al.
Publicado: (2022)

Magnetic Multi-Enzymatic System for Cladribine Manufacturing
por: Cruz, Guillermo, et al.
Publicado: (2022)

Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure
por: Malhotra, Sunny, et al.
Publicado: (2023)

Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta
por: Bustamante, Marta F., et al.
Publicado: (2013)

Cladribine modifies functional properties of microglia
por: Jørgensen, L. Ø., et al.
Publicado: (2020)

Cladribine: Lymphopenia: 2 case reports
Publicado: (2020)

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
por: Michels, Renée Else, et al.
Publicado: (2019)

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine
por: Schreiner, Teri L., et al.
Publicado: (2012)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9anl1reu86qp7sf1k9rhfl2bv5